The weeklong Antibody Therapeutics pipeline reveals the exciting developments in next-generation antibody therapeutics, including Antibody-Drug Conjugates, Bispecific Antibody Therapeutics, and Cancer Immunotherapies. Along with engineering breakthroughs,
this pipeline also explores successful R&D strategies, translational case studies, clinical results, and efficacy data for these promising molecules as they seek to conquer cancer and other diseases and promote human health.
Engineering Next-Generation Cancer Immunotherapies
Bispecific Antibody Therapeutics
Shahram Salek-Ardakani, PhD, Senior Director, Cancer Immunology Discovery, Pfizer
Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen, LLC
Partha S. Chowdhury, Senior Director, Biologics Research, Sanofi Genzyme